Vizsgálati helyszín
Alrijne Zorggroep Stichting
Leiderdorp, 2353 GA, HollandiaMég nincs intézményhez kötve
- 22futó vizsgálat
- 1lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 23 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis16 vizsgálat
- 4. fázis7 vizsgálat
- Állapot
- Toboroz13 vizsgálat
- Fut, nem toboroz8 vizsgálat
- Lezárult1 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Amsterdam UMC Stichting3 vizsgálat
- Leiden University Medical Center2 vizsgálat
- Novo Nordisk A/S2 vizsgálat
- Sanofi2 vizsgálat
- Amsterdam UMC1 vizsgálat
- és még 13
Futó vizsgálatok
Toboroz
ALBUMINUS: Dose reduction of human albumin during large-volume paracentesis in patients with cirrhosis
2026-526167-38-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Még nem toboroz
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás
Még nem toboroz
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
NCT07486687· 3. fázis· The Netherlands Cancer Institute· Forrás
Toboroz
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· 3. fázis· University Of Cologne· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347· 3. fázis· Sanofi· Forrás
Toboroz
Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial
2024-513092-40-00· 4. fázis· Stichting Radboud universitair medisch centrum· Forrás
Toboroz
inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT
NCT06581965· 4. fázis· Leiden University Medical Center· Forrás
Fut, nem toboroz
Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS)
NCT04225312· 4. fázis· Amsterdam UMC Stichting· Forrás
Fut, nem toboroz
DUTCH Weight Control in Atrial Fibrillation Study
NCT06184633· 4. fázis· Rijnstate Hospital· Forrás
Toboroz
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
NCT06275958· 3. fázis· Leiden University Medical Center· Forrás
Toboroz
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
NCT06187441· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS
2022-502664-21-00· 4. fázis· Amsterdam UMC· Forrás
Toboroz
An European multinational study of a personalized approach of human albumin administration in patients with cirrhosis of the liver and complications
2022-501006-34-01· 3. fázis· Odense University Hospital· Forrás
Fut, nem toboroz
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291· 3. fázis· University Medical Center Groningen· Forrás
Fut, nem toboroz
Personalized dosing of ocrelizumab in MS
2024-513193-22-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
NCT04774159· 3. fázis· Population Health Research Institute· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek